Market Overview

Benzinga's Top Downgrades

Benzinga's Top Downgrades
Related HAE
Haemonetics Rides on Solid Plasma, Slows Blood Center Growth
Haemonetics (HAE) Down 2.2% Since Earnings Report: Can It Rebound?

Analysts at Benchmark downgraded Haemonetics (NYSE: HAE) from “buy” to “hold.” The target price for Haemonetics has been lowered from $49 to $46. Haemonetics shares closed at $42.54 yesterday.

Hilliard Lyons downgraded Franklin Electric Co (NASDAQ: FELE) from “buy” to “neutral.” Franklin Electric's shares closed at $45.42 yesterday.

Latest Ratings for HAE

Feb 2017Barrington ResearchDowngradesOutperformMarket Perform
Nov 2016Barrington ResearchUpgradesMarket PerformOutperform
Aug 2016Sidoti & Co.DowngradesBuyNeutral

View More Analyst Ratings for HAE
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings


Related Articles (FELE + HAE)

View Comments and Join the Discussion!